Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of patritumab deruxtecan in solid tumors with NRG1 fusion
KCT0009451Phase 2Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of patritumab deruxtecan in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd.. Planned start May 2024; status: not yet recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on KCT0009451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009451.